tbuckley/cabot-search huggingface dataset:
Sullivan, Horner, and Mason Nominated to Lead DHHS
Authors: K. Smigel
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Sullivan, Horner, and Mason Nominated to Lead DHHS Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 6, 15 March 1989, Pages 398–399, https://doi.org/10.1093/jnci/81.6.398 Published: 15 March 1989
Shedding of<i>Mycoplasma pneumoniae</i>after Tetracycline and Erythromycin Therapy
Authors: Charles B. Smith, William T. Friedewald, Robert M. Chanock
Journal: New England Journal of Medicine (1967)

MOST early studies of the efficacy of antimicrobial treatment of atypical pneumonia were inconclusive because at that time many of the etiologic agents responsible for this syndrome were not known.1 The development of a sensitive and specific serologic test for infection with the Eaton agent by Liu et al.2 led to the demonstration that this agent was an important cause of atypical pneumonia.3 Later, it was shown that dimethylchlortetracycline was effective in the treatment of pneumonia due to the Eaton agent.4 The successful growth of the Eaton agent on an artificial medium5 and its subsequent identification as a mycoplasma ( . . .
The Probable Systemic Nature of Mikulicz's Disease and Its Relation to Sjögren's Syndrome
Authors: Winfield S. Morgan
Journal: New England Journal of Medicine (1954)

IN 1892 Mikulicz1 described a case of benign, asymptomatic, symmetric enlargement of the lacrimal and salivary glands. Microscopical examination of excised portions of the glands disclosed atrophy of the acinar parenchyma and diffuse replacement by lymphoid tissue. Apparently, this was the first report of its kind given much attention in the literature, and in time the condition received the name "Mikulicz's disease." In the years that followed this became a very confused subject. Many cases manifesting enlargement of the salivary or lacrimal glands were diagnosed as Mikulicz's disease with little attention to the histopathology. Later, it became apparent that bilateral . . .
AB0345 Clinical Evaluation of Anti-Aminoacyl T-Rna Synthetase Antibody in Rheumatoid Arthritis Patients
Authors: M. Matsushita, T. Kawamoto, K. Yamaji, N. Tamura, Y. Takasaki
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> Anti-Jo-1 antibody is an autoantibody specifically detected in the serum of patients with polymyositis (PM) or dermatomyositis (DM). The homologous antigen of anti-Jo-1 antibody is a histidyl tRNA synthetase, one of the aminoacyl tRNA synthetases (ARS) found in cytoplasm. A number of antibodies homologous to other ARSs have been identified recently. Lung and skin diseases observed characteristically in patients with anti-Jo-1 antibody are collectively called anti-ARS antibody syndrome. We measured the anti-ARS antibody level in rheumatoid arthritis (RA) patients and evaluated the clinical characteristics of their symptoms. <h3>Methods</h3> This study included 234 RA outpatients treated at our clinic to evaluate their anti-ARS antibody level, antinuclear antibody prevalence and staining pattern, concurrent interstitial pneumonia (IP), joint symptoms and Raynaud9s phenomenon, concurrent PM/DM, and medications including biological drugs. The anti-ARS antibody level was measured using Myositis Profile 3 EUROLINE (EUROIMMUNE, Lubeck, Germany) according to the manufactures instructions. <h3>Results</h3> Anti-ARS antibodies were detected in 18 patients (7.7%). Specifically, anti-PL-7 antibody was detected in 7 patients (3.0%), anti-EJ antibody was detected in 6 patients (2.6%), anti-Jo-1 antibody was detected in 2 patient (0.9%), anti-PL-12 antibody was detected in 2 patients (0.9%), and anti-OJ antibody was detected in 1 patient (0.4%). The evaluation of clinical characteristics found concurrent IP in 42.8% of anti-EJ antibody-positive patients, no anti-OJ antibody-positive patients, 71.4% of anti-PL-7 antibody-positive patients, and all anti-PL-12 antibody-positive patients. The results suggest anti-PL-12 antibody and anti-PL-7 antibody are IP-related autoantibodies. In patients with concurrent IP, the prevalence was significantly high (33.3%). The evaluation of non-IP clinical presentations in anti-ARS antibody positive patients found no noteworthy characteristics such as arthritis, skin symptoms, and use of specific medications. Biological drugs were used in 3 anti-ARS antibody-positive patients safely without inducing myositis or aggravating IP. <h3>Conclusions</h3> Of the anti-ARS antibodies specifically detected in PM/DM patients, anti-PL-7 and anti-PL-12 antibodies were detected in RA patients with concurrent IP at a significantly high frequency, suggesting these autoantibodies are associated with IP. Biological drugs may be used safely in patients tested positive for these autoantibodies. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1734
Abstract LB-354: Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis
Authors: Bhavna Kumar, Arti Yadav, Theodoros N. Teknos, Pawan Kumar
Journal: Cancer Research (2010)

Abstract Objectives of the study: Head and Neck squamous cell carcinoma (HNSCC) results from deregulation of multiple signaling pathways leading to tumor cells acquiring proliferative, invasive, angiogenic and metastatic properties. Interactions between neoplastic cells and the surrounding microenvironment also play a major role in tumor progression. Recent studies have demonstrated that microRNA's (miRs) play a critical role in cancer development where they can act as oncogenes or as onco-suppressors. A microRNA array analysis of a panel often HNSCC cell lines reveled that miR-34a is significantly downregulated in all these cell lines as compared to normal human oral keratinocyes (HOK). In addition, miR-34a expression was also downregulated in highly angiogenic endothelial cells (endothelial cells overexpressing Bcl-2; EC-Bcl-2) as compared to normal human endothelial cells. However, little is known about the role of miR-34a in HNSCC tumor growth and tumor angiogenesis. In this study, we examined if dysregulation of miR-34a in HNSCC promotes tumor growth and tumor angiogenesis. Methodology: The study was performed using a panel of established human head &amp; neck cancer cell lines. miRs expression in tumor and endothelial cells was examined by miR-arrays and further validated by real time PCR. Lipofectamine-2000 was used to transfect miR-34a in 2 HNSCC cell lines (UM-SCC-74A and UM-SCC-47) and human endothelial cells. Cell-proliferation assay was performed by MTT and colony formation assay. Tumor cell and endothelial cell motility was assessed by scratch assay. Expression of miR-34a downstream mediators was measured by Western blot. Results: Ectopic expression of miR34a significantly inhibited cell proliferation of UM-SCC-74A cells (52% and 58% on days 2 and 4) and UM-SCC-47 cells (43% and 47% on days 2 and 4). In addition, enhanced expression of miR34a in UM-SCC-74A and UM-SCC-47 cells significantly inhibited tumor cell colony formation and tumor cell migration. Similar to tumor cells, miR-34a significantly inhibited EC-Bcl-2 proliferation and migration by down regulating c-met, Bcl-2 expression and upregulating phospho p38 MAPK expression. Conclusion: These findings indicate that dysregulation of miR-34a expression is common in HNSCC and modulation of miR34a activity might represent a novel therapeutic strategy for the treatment of head and neck cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-354.
Angiogenic biomaker study in osteosarcoma
Authors: P. C. Pavoni-Ferreira, A. S. Petrilli, M. T. Alves, R. Jesus-Garcia Filho, S. R. Toledo
Journal: Journal of Clinical Oncology (2009)

e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients. Methods: Tumor samples from 27 patients were analyzed before and after chemotherapy to determine VEGFA, VEGFR1, VEGFR2, PDGFC, SDF1 and TSP1 genes expression profile by Quantitative Real Time PCR. Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity. Results: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed. SDF1 gene has the lowest expression at all. In tumor samples, TSP1 and VEGFA expression was higher than SDF1, VEGFR2 and PDGFC expression in biopsies and surgeries (P=0.001). VEGFR1 expression was higher than VEGFR2 expression (P=0.001). PDGFC and VEGFR1 overexpression were associated with necrosis grade I and II (Huvos score) (P=0.005). VEGFA and TSP1 were overexpressed in 96% and 92% of surgery samples, respectively. In blood samples from biopsy, surgery and end of treatment there were no statistically significant changes in the marker genes expression. Conclusions: The study suggests an association between PDGFC and VEGFR1 overexpression and lower grade necrosis. TSP1 and VEGFA were the most expressed genes in all tumor samples but TSP1 was lower than VEGFA in biopsies and VEGFA was lower than TSP1 in surgery (P=0.001). Although VEGFR2 is the primary receptor of VEGF, VEGFR1 was the most expressed VEGF receptor. No significant financial relationships to disclose.
BI-02 * DISRUPTION OF PERIVASCULAR ASTROCYTIC FOOT PROCESSES CHARACTERIZES MRI ENHANCEMENT IN PEDIATRIC BRAIN TUMORS
Authors: C. Hong, M. Piazza, W. Ho, Z. Zhuang
Journal: Neuro-Oncology (2015)

Preservation of cross-talk between endothelial cells and astrocyte foot processes is vital to the integrity of the blood-brain barrier (BBB). The water channel protein, aquaporin-4 (AQ4), is polarizingly located at astrocytic foot processes surrounding vasculature. This study investigated whether disruption of the normal relationship between endothelial cells and astrocytic foot processes accounts for enhancement on magnetic resonance imaging (MRI) in three common pediatric brain tumors. Immunofluorescence was performed on surgically resected samples of pilocytic astrocytoma (n = 5), medulloblastoma (n = 5), and low-grade glioma (LGG; n = 1), utilizing antibodies against CD31 (an endothelial cell marker), GFAP, and AQ4. Additionally, clinical, radiographic, and histopathological parameters were collected. Radiographically, there was strong, moderate, and absent contrast enhancement of medulloblastomas, pilocytic astrocytomas, and LGG, respectively. Immunofluorescent staining demonstrated complete breakdown of the endothelial cell-astrocytic foot process relationship in medulloblastomas, characterized by scarce perivascular GFAP and AQ4 signals. In pilocytic astrocytomas, there was strikingly disorganized and disproportionately reduced AQ4 staining compared to the strong density of GFAP. In LGG, there was remarkably tight juxtaposition of AQ4 and GFAP signals, such that visualization of AQ4 alone could accurately delineate CD31-positive vasculature. BBB breakdown at the level of the relationship between endothelial cells and perivascular astrocytic foot processes reflected the extent of MRI enhancement in the studied tumors. In strongly-enhancing medulloblastoma, the predominant absence of GFAP- and AQ4-positive cells suggests complete perivascular denuding of astrocyte foot processes and reflects a likely non-glial cell of origin in this tumor. In pilocytic astrocytoma and LGG, GFAP abundance is consistent with the astrocytic nature of these tumors. However, unlike in LGG, AQ4 in pilocytic astrocytoma was disorganized around microvasculature, suggesting the tumor cells, despite being astrocyte-derived, cannot fulfill their physiological role of BBB support. Furthermore, AQ4 polarity around vasculature may better predict BBB integrity than perivascular GFAP in astrocytic tumors.
A Report of Congenital Heart Disease in Five Members of One Family
Authors: Max H. Weil, Bertram J. Allenstein
Journal: New England Journal of Medicine (1961)

This report documents for the first time§ the occurrence of congenital intracardiac defects in more than 4 members of 1 family, and thus offers another challenge and a clue in the study of etiology of congenital heart defects. Five members of the family proved to have defects of the atrial septum, and the same diagnosis is strongly suspected on clinical grounds in 3 additional members, pointing to the probability of hereditary transmission.Recently, efforts have been made to demonstrate hereditary transmission of congenital heart defects on the basis of the finding of multiple cases in the same family. The hypothesis . . .
Abstract 2847: Host angiopoietin-2 inhibits tumor growth and angiogenesis in the liver
Authors: Jae Hong Im, Lukxmi Balathasan, Sabira Yameen, Thomas Tapmeier, Sally Hill, Eric Bernhard, D.Lee Gorden, Karoline Kruse, Hellmut Augustin, Ruth J. Muschel
Journal: Cancer Research (2011)

Abstract For growth and survival in metastasis, tumor colonies must develop new intratumoral vasculature for supply of nutrients and oxygen. Since angiopoietin-2 (Ang2) resulted in a burst of angiogenesis in the glioma model, we examined the effects of host Ang2 on colony growth and neo-angiogenesis during the liver colonization. Liver colonization was induced through the intrasplenic injection of MC38-GFP (murin colorectal carcinoma cells) into two genotype mice of the ang2−/− mice and the wild type mice. When colonies were established, the livers were isolated and analyzed using flow cytometry, immunoflorescent histochemistry and ELISA. In addition, the blood was collected from vena cava for measurement of MCP-1 at 14 days. Flow cytometry analyses of whole livers showed that the tumor cell population in the ang2−/− mice was approximately 2 times larger than in the wild type mice. Immunoflorescent histochemistry of the liver tissue using antibodies for CD31, CD34, CD146, VE-cadherin and NG2 showed that intratumoral vascular density and vascular maturity in the ang2−/− mice were approximately 2 times higher than the wild type mice. Intratumoral vessels were significantly positive for CD146 and CD34, markers more frequently associated with neo-angiogenesis, but much less for CD31. There was no significant difference in VEGF level which is known to mediate vascular response in combination with Ang2. CD11b positive cells and MCP-1 concentration in the livers were equivalent in two genotypes. Notably, there were approximately 10 times more Tie2+/CD11b+ cells in the ang2−/− mice than the wild type mice. CD11c+/CD45+ cell populations were slightly different in two genotypes. These results suggested that host Ang2 would inhibit tumor growth and neo-angiogenesis in the liver, and that the inhibition is correlated with the decreased recruitment of TEMs, one of myeloid cells, into the liver. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2847. doi:10.1158/1538-7445.AM2011-2847
AB0578 Anti-tnfa therapy in psoriatic arthritis: different rate of remission in polyarticular and oligoarticular subsets
Authors: F. Iannone, S. Lopriore, R. Bucci, C. Scioscia, M. G. Anelli, M. Covelli, G. Lapadula
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To compare the efficacy of adalimumab, etanercept, and infliximab therapy in psoriatic arthritis (PsA) patients with oligoarticular or polyarticular subset <h3>Methods</h3> We enrolled in a prospective, not-randomized, open-label study 349 PsA patients with peripheral disease, 234 with polyarticular and 115 with oligoarticular subset, beginning a treatment with adalimumab, etanercept, or infliximab. At baseline, 6 months, and 12 months, disease activity indices, (DAS28, Disease Activity Score on 28 joints, SDAI, simplified disease activity index, sum of TJC tender joint count, SJC swollen joint count, CRP C-reactive protein, and PzGA Patient Global Assessment), and disability HAQ (Health Assessment Questionnaire) were calculated. The rates of disease remission were compared among the three TNF-ablockers at 6 and 12 months. Baseline predictors of disease remission and functional improvement (reduction of HAQ ≥0.5) were analyzed by multivariate regression models <h3>Results</h3> After 12 months the percentage of patients on clinical remission (SDAI ≤3.3) was significantly higher in infliximab or etanercept than adalimumab group (p&lt;0.05), both in oligoarticular and polyarticular subset. Infliximab induced the widest decrease of TJC and the best "good" EULAR response in polyarthritis and oligoarthritis patients, respectively. Baseline predictors of disease remission were low DAS28, low HAQ, sex male, and glucocorticoids therapy in polyarthritis. The best predictor of functional improvement (ΔHAQ ≥0.5) was high HAQ in both subsets. <h3>Conclusions</h3> Our study provides evidence that anti-TNFa drugs may differently perform in PsA and that separate analysis of the clinical subsets of the disease may improve our knowledge of the management of PsA <h3>Disclosure of Interest</h3> None Declared
P1199 RE-TREATMENT WITH TELAPREVIR-BASED TRIPLE THERAPY AFTER TELAPREVIR EXPOSURE IN PHASE 1 STUDIES: DEEP SEQUENCE ANALYSIS FOR PERSISTENCE OF RESISTANT VARIANTS
Authors: S. Susser, M. Flinders, H.W. Reesink, S. Zeuzem, G. Lawyer, A. Ghys, V. Van Eygen, J. Witek, S. De Meyer, C. Sarrazin
Journal: Journal of Hepatology (2014)
Homocysteine and Atherothrombosis
Authors: George N. Welch, Joseph Loscalzo
Journal: New England Journal of Medicine (1998)

In 1969, McCully made the clinical observation linking elevated plasma homocyst(e)ine concentrations with vascular disease.1 He reported autopsy evidence of extensive arterial thrombosis and atherosclerosis in two children with elevated plasma homocyst(e)ine concentrations and homocystinuria. On the basis of this observation, he proposed that elevated plasma homocyst(e)ine (hyperhomocyst(e)inemia) can cause atherosclerotic vascular disease. The term "homocyst(e)ine" is used to define the combined pool of homocysteine, homocystine, mixed disulfides involving homocysteine, and homocysteine thiolactone found in the plasma of patients with hyperhomocyst(e)inemia.Subsequent investigations have confirmed McCully's hypothesis, and it has recently become clear that hyperhomocyst(e)inemia is an independent risk factor . . .
Stat Bite: Canadian Cancer Ratios
Authors: L. A. Gaudette
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Stat Bite : Canadian Cancer Ratios Get access Leslie A. Gaudette Leslie A. Gaudette Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 23, 1 December 1993, Page 1893, https://doi.org/10.1093/jnci/85.23.1893 Published: 01 December 1993
Aspirin and Dipyridamole in the Prevention of Re-Stenosis after Percutaneous Transluminal Coronary Angioplasty
Authors: Leonard Schwartz, Martial G. Bourassa, Jacques Lespérance, Harold E. Aldridge, Farouk Kazim, Vincent A. Salvatori, Mark Henderson, Raoul Bonan, Paul R. David
Journal: New England Journal of Medicine (1988)

To examine the role of antiplatelet therapy in the prevention of arterial restenosis after percutaneous transluminal coronary angioplasty (PTCA), we conducted a randomized, double-blind, placebo-controlled study in 376 patients. The active treatment consisted of an oral aspirin-dipyridamole combination (330 mg-75 mg) given three times daily, beginning 24 hours before PTCA. Eight hours before PTCA, the oral dipyridamole was replaced with intravenous dipyridamole at a dosage of 10 mg per hour for 24 hours, and oral aspirin was continued. Sixteen hours after PTCA, the initial combination was reinstituted. Treatment was continued in patients with a successfully dilated vessel until follow-up angiography four to seven months after PTCA--or earlier, if symptoms dictated. Of 249 patients who underwent follow-up angiography, 37.7 percent of patients receiving the active drug had restenosis in at least one segment, as compared with 38.6 percent of patients taking placebo (P not significant). The number of stenotic segments was virtually the same in the two groups. Among the 376 randomized patients, there were 16 periprocedural Q-wave myocardial infarctions--13 in the placebo group and 3 in the active-drug group (6.9 percent vs. 1.6 percent, P = 0.0113). Although the use of this antiplatelet regimen before and after PTCA did not reduce the six-month rate of restenosis after successful coronary angioplasty, it markedly reduced the incidence of transmural myocardial infarction during or soon after PTCA. Thus, the short-term use of antiplatelet agents in relation to PTCA can be recommended.
A SYSTEMATIC REVIEW AND META-ANALYSIS: PREVALENCE OF CORONARY PLAQUE HIGH-RISK FEATURES (LOW ATTENUATION, ENLARGED DIAMETER OR POSITIVE REMODELING, NAPKIN RING, AND SPOTTY CALCIFICATION (LENS) IN ACUTE CORONARY SYNDROME AS ASSESSED BY CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY (CTA)
Authors: Muhammad A. Latif, Ricardo Cury, Maham Akhlaq, Emir Veledar, Juan C. Batlle, Muhammad Aziz, Rehan Malik, Adnan Younus, Imran Haider, Shozab Ali, Warren Janowitz, Arthur Agatston, Khurram Nasir
Journal: Journal of the American College of Cardiology (2016)
AB0827-HPR Alexithymia phenomenon in systemic sclerosis patients
Authors: M. B. Ramkhelawon, S. A. Kharchenko, R. A. Grekhoff, G. P. Suleimanova, I. A. Zborovskaya
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> Our aim was to study the phenomenon of alexithymia – a special mental quality of psychosomatic personality in systemic sclerosis patients. <h3>Methods</h3> We observed 54 patients suffering from systemic sclerosis (SS) using Toronto Alexithymia Scale (TAS). The majority of patients were women (94, 4%) of 45, 59 ± 1, 65 years in average. Average duration of the disease was 4, 42 ± 0, 44 years. 1st degree of SS activity has been diagnosed in 12 (22, 2%) patients, 2nd degree - in 37 (68, 5%) and 3rd degree - in 5 (9, 3%) patients. The chronic clinical course of the disease was observed in 16 (29, 6%) patients, subacute course of the disease - in 35 (64, 8%) and acute course - in 3 (5, 5%) patients. <h3>Results</h3> The data we obtained shows evidence of high level of alexithymia in SS patients (77,35 ± 1,8 test scores). Besides the results of our research, alexithymia was seen to play a certain role in the pathogenesis of psychosomatic disturbances in SS. Alexithymia doesn't depend on gender and age of patients. The clinical course and activity of the disease on the one hand, reliably has a negative correlation between alexithymia expression and educational level of patients (r=-0,37 at p=0,028). Internality in the relation to disease (r=-0,64 at p=0,031), was also reliably in a direct correlation with "Jet formations" mechanism of psychological defense (r=0,58 at p=0,023) which was revealed on the other hand. <h3>Conclusions</h3> Thus, there are certain correlations between alexithymia development and some clinical and psychological characteristics of SS patients. Understanding the correlations is important in order to organize preventive psychological interventions with the purpose to correct alexithymic traits. <h3>Disclosure of Interest</h3> None Declared